Hirth Peter
Transaction: 06/25/2026
BUY
Change
+5,860
Price
$5.50
Filing
06/29/2026
Type
BUY
Aligos Therapeutics, Inc.
ALGS • Biotechnology
$6.21
▼ -0.01 (-0.16%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$64.78M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 19.2%Manageable debt level · 0.1Healthy liquidity · 3.9Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:46 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$6.21
Change-0.16%
Shares Out10.43M
Market Cap$64.78M
Enterprise Value$37.90M
52W Range3.98 - 13.69
Beta2.26
P/E-0.92
P/S17.32
P/B2.03
P/FCF-0.69
EV/Sales10.13
Price$6.21
Change-0.16%
Shares Out10.43M
Market Cap$64.78M
Enterprise Value$37.90M
52W Range3.98 - 13.69
Beta2.26
P/E-0.92
P/S17.32
P/B2.03
P/FCF-0.69
EV/Sales10.13
EV/EBITDA-0.47
EV/FCF-0.40
Earnings Yield-108.59%
FCF Yield-145.92%
Dividend Yield0.00%
Gross Margin57.46%
Oper. Margin-40.25%
Profit Margin-11.07%
Debt/Eq0.10
Current Ratio3.90
Quick Ratio3.90
Target$20.00
Target Upside222.06%
Target Median$20.00
Target Range20.00 - 20.00
Volume10.68K
Avg Volume173.70K
EPS Surprise0.08
Investment DNA
How strong this company looks for long-term investors
48
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
54/100
Why this score▼
Positive revenue growth · 19.2%Manageable debt level · 0.1Healthy liquidity · 3.9Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 5 analyst votes · 2026-09-05
80/100
Bullish
Bullish
3
Hold
2
Bearish
0
Price Target
2026-08-07
Low
$20.00
Mean
$20.00
Median
$20.00
High
$20.00
Insider Transactions
Recent executive and insider activity
Nuechterlein Carole
Transaction: 06/25/2026
BUY
Change
+5,860
Price
$5.50
Filing
06/29/2026
Type
BUY
Scopa James Paul
Transaction: 06/25/2026
BUY
Change
+5,860
Price
$5.50
Filing
06/29/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Hirth Peter | BUY | +5,860 | $5.50 | 06/25/2026 | 06/29/2026 |
| Nuechterlein Carole | BUY | +5,860 | $5.50 | 06/25/2026 | 06/29/2026 |
| Scopa James Paul | BUY | +5,860 | $5.50 | 06/25/2026 | 06/29/2026 |
| Martell Bridget A | BUY | +5,860 | $5.50 | 06/25/2026 | 06/29/2026 |
| Chavez Margarita | BUY | +5,860 | $5.50 | 06/25/2026 | 06/29/2026 |
| Preston Heather | BUY | +5,860 | $5.50 | 06/25/2026 | 06/29/2026 |
| Symons Julian A. | BUY | +23,310 | $7.03 | 03/09/2026 | 03/11/2026 |
| BLATT LAWRENCE | BUY | +105,840 | $7.03 | 03/09/2026 | 03/11/2026 |
| Calhoun Lesley Ann | BUY | +37,485 | $7.03 | 03/09/2026 | 03/11/2026 |
| Aneja Nikhil | BUY | +9,450 | $7.03 | 03/09/2026 | 03/11/2026 |
| Aneja Nikhil | OTHER | +3,600 | $8.68 | 01/29/2026 | 02/19/2026 |
| Calhoun Lesley Ann | BUY | +40,185 | $8.68 | 07/16/2025 | 07/18/2025 |
| Symons Julian A. | BUY | +16,000 | $8.68 | 07/16/2025 | 07/18/2025 |
| BLATT LAWRENCE | BUY | +179,800 | $8.68 | 07/16/2025 | 07/18/2025 |
| Martell Bridget A | BUY | +5,860 | $7.63 | 06/25/2025 | 06/26/2025 |
| Chavez Margarita | BUY | +5,860 | $7.63 | 06/25/2025 | 06/26/2025 |
| Preston Heather | BUY | +5,860 | $7.63 | 06/25/2025 | 06/26/2025 |
| Hirth Peter | BUY | +5,860 | $7.63 | 06/25/2025 | 06/26/2025 |
| Scopa James Paul | BUY | +5,860 | $7.63 | 06/25/2025 | 06/26/2025 |
| Nuechterlein Carole | BUY | +5,860 | $7.63 | 06/25/2025 | 06/26/2025 |